This study is looking at whether adding the medication tirzepatide (Mounjaro) after sleeve gastrectomy surgery can help people lose more weight. It also aims to see if this combination better improves conditions like Type 2 diabetes, high blood pressure (hypertension), high cholesterol (hyperlipidemia), and sleep apnea, and if it causes more side effects compared to surgery alone. You might be able to join if you are an adult between 18 and 65 years old, have a Body Mass Index (BMI) over 35 with certain health conditions, or a BMI over 40. You must also be planning to have sleeve gastrectomy surgery. The main goal is to measure weight loss 12 months after surgery. The current status of this study is unclear, and it plans to enroll 42 participants.

Study design

This is a randomized control trial involving 42 participants. Half will receive sleeve gastrectomy and tirzepatide, and the other half will receive sleeve gastrectomy alone.

What's involved

Participants in both groups will undergo sleeve gastrectomy. Those receiving tirzepatide will have a 4-week dose escalation period, then receive weekly 2.5mg doses for 4 weeks starting at 6 months after surgery.

Compensation

Not stated in the trial record.

Follow-up

Weight loss will be measured at 12 months after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.